Delineate
Delineate builds agentic systems for Model-Informed Drug Development. Its agents search PubMed and ClinicalTrials.gov, rank studies against custom criteria, and use computer vision to pull data from PK/PD plots, Kaplan-Meier curves and tables. It also offers a web-based modeling workstation with R, Python and Julia. It sells to pharma and biotech companies as a SaaS product. The company is Y Combinator Winter 2025 backed, and its BIO 2026 listing cites a $3.2M seed round and an active NIH grant. Investors listed on Crunchbase include Unpopular Ventures and Y Combinator.
Funding
Every round, secondary, debt facility or acquisition involving Delineate that AI Lounge tracks, newest first.
No rounds recorded yet.
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in